GSK strikes up to $750 million deal for cancer-targeting drug
GSK LSE:GSK said on Tuesday it had agreed to a deal worth up to $750 million to buy a trispecific T cell-engager, a drug designed to help T-cells target cancer, from private biotechnology firm Chimagen Biosciences.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.